This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
News & Press: Regulatory Updates

PHSS June 2020 Regulatory Update:EU COVID-19: What's new; MHRA GDP process changes

10 June 2020  
Posted by: Tamsin Marshall
Share |

PHSS Regulatory Update June 2020 available for download for members! Login to view

During the last 4 weeks there have been a number of developments in the regulation of the pharmaceutical industry. This month reported issues have come from the Australian, Chinese, EU, UK and PIC/s regulatory authorities.

The topics covered in this edition of the “Update” include:

 

European Union

  • COVID-19: What's new
  • EU actions to support availability of medicines during COVID-19 pandemic – update #5
  • Decision on fee reductions (GMP) on-site inspections due to COVID-19 pandemic
  • Q&A- regulatory expectations for medicinal products for human use during the COVID-19 Pandemic (rev 1)
  • Deadline postponed for the second targeted consultation on Annex 1
  • Post-authorisation measures: Q&A
  • Risk management plan (RMP): Q&A
  • Transfer of marketing authorisation: Q&A
  • Renewal and annual re-assessment of marketing authorisation
  • Checklist for Initial Notifications for Parallel Distribution
  • Minutes of the 107th meeting of the EMA Management Board

UK

MHRA

  • How to manage temporary GDP process changes and risks through the COVID-19 pandemic

 
International

USA

  • General considerations for pre-IND meeting requests for COVID-19 related drugs and biological products
  • Recommendations for the permitted daily exposures for three solvents—2-methyltetrahydrofuran,cyclopentyl methyl ether, and tert-butyl alcohol—according to the maintenance procedures for the guidance Q3C (R8)impurities:residual solvents

  • Orange Book Q&A Guidance for Industry (draft)

Australia

Therapeutic Goods Administration (TGA) 

  • Update to Manufacturing Principles for medicines, APIs & sunscreens
  • Reuse of face masks and gowns during the COVID-19 pandemic

China
  • National Medical Products Newsletter 2020 Volume 3

PIC/S

  • Adoption and Entry into Force of New PIC/S Guidance Documents (PI 052-1 and PI 053-1)

Products

  • New vaccine for prevention of Ebola virus disease recommended for approval in the EU

Membership Software Powered by YourMembership  ::  Legal